Container: Plain (red top) or gel tube
Collection protocol: Due to long elimination half-life, samples can be collected at any time >2 hours after dosing to avoid any peak effect variability.
Special handling/shipping requirements: Standard
General information about the disease: Used as an anti-epileptic drug commonly in conjunction with phenobarbitone (PB) or as monotherapy in dogs with hepatic dysfunction, in large-breed dogs and working dogs in which side effects from PB are unacceptable.
Signs of bromide toxicity include: stupor or coma, blindness, ataxia, tetraparesis, dysphagia, and megaoesophagus. When being used with phenobarbital, sedation and weakness may become evident. Clearance may be decreased in dogs with impaired renal function.
- At 1 and 3 months after therapy has been initiated then yearly after that.
- A month after a change of dose.
- If there are more than 3 seizures before the next scheduled assessment or if signs of toxicity are suspected.
- If the dog is on PB therapy when KBr is added to the therapeutic regime then serum PB concentration should also be measured 4-6 weeks after KBr introduction. KBr seems to enhance the excretion or metabolism of PB and frequently the serum PB concentration drops after KBr is introduced.
Monotherapy: 100-300 mg/dL
Combination with phenobarbital: 80-250 mg/dL
Podell M et al. 2015 ACVIM Small animal consensus statement on seizure management in dogs. Journal of Veterinary Internal Medicine 30:477-490, 2016 Taylor SM. Neuromuscular Disorders.In Nelson RW and Couto CG, (Eds). Small Animal Internal Medicine 5th edition. Pp1024. Elsevier Mosby, St. Louis Missouri, USA, 2014